NASDAQ$NPCE
Neuropace Inc · Q1 2025 earnings
Q1 2025 earnings · · After market close · Investor relations
Briefing
NeuroPace reported a 24% year-over-year revenue increase in Q1 2025, driven by strong demand for its RNS System and improved operating leverage.
NeuroPace delivered record Q1 2025 revenue of $22.5 million, supported by growth in its core RNS System line and strong gross margins. Net loss narrowed compared to the prior year, and the company ended the quarter with a robust cash position.
- Achieved record quarterly revenue of $22.5 million, up 24% year-over-year
- Gross margin reached 77.0%, exceeding full-year guidance
- Operating loss narrowed to $5.1 million from $7.5 million in Q1 2024
- Ended the quarter with $66.3 million in cash, cash equivalents, and short-term investments
Headline financials
Revenue & EPS history
Neuropace · Revenue · Quarterly
$22.5M
Revenue by segment
Neuropace · $1.6M total across 1 segment · Q4 2022
- DIXI Medical$1.6M—100.0%
Forward guidance
NeuroPace raised full-year 2025 revenue guidance to $93–97 million and expects gross margin between 73% and 75%, supported by strong commercial momentum.
Tailwinds
- Increased full-year 2025 revenue guidance to $93–97 million
- Projected gross margin of 73%–75% aligns with Q1 performance
- Expanded physician base driving RNS adoption
- New real-world data supports best-in-class efficacy of RNS System
- AI-powered software development remains on track
Headwinds
- Ongoing net losses despite revenue growth
- SEEG distribution agreement to be wound down
- R&D investment pressures short-term profitability
- Long-term debt stands at $59.8 million
- Continued dependence on single product line for growth
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 19 quarterly earnings reports · overlaid with Q1 2025
-0.7%
Avg return
Earnings day
-1.0%
Avg return
5 days after
-0.1%
Avg return
30 days after
50%
12 / 24 earnings
Positive
+37.4%
Q3 2025
Best reaction
-40.1%
Q1 2024
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | +0.6% | -1.8% | — | |
| Q4 2025 | +1.1% | +1.6% | +5.9% | |
| Q3 2025 | +37.4% | +43.1% | +74.5% | |
| Q1 2025 | +21.6% | +31.3% | -14.5% | |
| Q4 2024 | -2.4% | -15.8% | +2.6% | |
| Q3 2024 | +25.7% | +23.4% | +49.9% | |
| Q2 2024 | -1.9% | -0.4% | +4.8% | |
| Q1 2024 | -40.1% | -35.9% | -51.4% | |
| Q4 2023 | +0.8% | +2.5% | -8.4% | |
| Q3 2023 | -1.4% | +9.5% | +14.6% | |
| Q2 2023 | +9.8% | +9.8% | +103.4% | |
| Q1 2023 | +1.9% | -3.5% | -15.4% | |
| Q4 2022 | -13.3% | -7.8% | -1.9% | |
| Q3 2022 | -9.9% | -17.6% | -29.6% | |
| Q2 2022 | -3.5% | -10.2% | -26.6% | |
| Q1 2022 | +1.2% | -3.6% | -3.8% | |
| Q4 2021 | -0.9% | -7.7% | -1.2% | |
| Q3 2020 | -15.2% | -22.2% | -47.7% | |
| Q3 2021 | -15.2% | -22.2% | -47.7% | |
| Q2 2021 | -7.6% | -10.7% | -8.0% | |
| Q2 2020 | -7.6% | -10.7% | -8.0% | |
| Q1 2020 | +0.8% | +8.7% | +2.2% | |
| Q1 2021 | +0.8% | +8.7% | +2.2% | |
| Q4 2020 | +0.8% | +8.7% | +2.2% |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro